Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Support us
Support us
  • Home
  • Frank van Leeuwen

Frank van Leeuwen

Group leader
Dr. Frank van Leeuwen leads a research group in the Princess Máxima Center. His team focuses on genetic aberrations that lead to pediatric acute lymphoblastic leukemia.

Publications

101 publications in total

  • CpG island methylator phenotype classification improves risk assessment in pediatric T-cell acute lymphoblastic leukemia

    • mei 2025
    • Fernanda, Schäfer Hackenhaar, et al
    • Blood

  • Loss of p53 impairs death receptor expression and confers resistance to CD19 CAR T-cell therapy in BCP-ALL

    • feb. 2025
    • Willem P.J., Cox, et al
    • Blood neoplasia

  • Loss of p53 impairs death receptor expression and confers resistance to CD19 CAR T-cell therapy in BCP-ALL

    • feb. 2025
    • Willem, Cox, et al
    • Blood Neoplasia

  • Underlying biology, challenges and emergent concepts in the treatment of relapsed and refractory pediatric T-cell acute lymphoblastic leukemia

    • jan. 2025
    • Patrícia, Amaral, et al
    • Leukemia

  • Treatment-related mutagenic processes in acute lymphoblastic leukemia

    • jan. 2025
    • Cédric G., van der Ham, et al
    • Haematologica
View all publications